Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as lansoprazole
Lansoprazole and AZD4635 solid formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | lansoprazole 60 mg + clopidogrel 300 mg/ 75 mg |
| 2 | EXPERIMENTAL | omeprazole 80 mg + clopidogrel 300/75 mg |
| 3 | EXPERIMENTAL | esomeprazole 40 mg + clopidogrel 300/75 mg |
| 4 | EXPERIMENTAL | clopidogrel 300/75 mg alone |
| Name | Type | Description |
|---|---|---|
| lansoprazole | DRUG | 60 mg (2x30-mg capsule), once daily |
| omeprazole | DRUG | 80 mg (2x40-mg capsule), once daily |
| esomeprazole | DRUG | 40 mg (1x40-mg capsule), once daily |
| clopidogrel | DRUG | 300 mg loading dose on Day 1 then 75 mg daily for 28 days |
Inclusion Criteria: * Healthy males within the age of 18-45 years and females within the age of 18-55 years with suitable veins for cannulation or repeated vein puncture. Females must be of non-childbearing potential. * Weight of 50-95kg, inclusive, and a BMI between 19-30 kg/m2, inclusive. * No cl...
Lansoprazole and AZD4635 solid formulation is an investigational small molecule combination developed by AstraZeneca PLC. It pairs lansoprazole, a proton pump inhibitor, with AZD4635 in a single oral solid dose. The combination has been studied in a Phase 1 clinical trial, and the specific indication has not been disclosed.
Lansoprazole and AZD4635 solid formulation targets ATP4A and ATP4B, the subunits of the gastric proton pump. It acts as an inhibitor of these targets. This mechanism is associated with suppression of gastric acid secretion, which is the pharmacological basis for including lansoprazole in the combination.
AstraZeneca PLC, which trades under the ticker AZN, is the developer of lansoprazole and AZD4635 solid formulation. The company is responsible for the clinical development of this investigational combination product.
Lansoprazole and AZD4635 solid formulation is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this formulation.
Lansoprazole and AZD4635 solid formulation has been evaluated in one completed Phase 1 trial, NCT01147588. That study enrolled 149 healthy adult volunteers in the United States and examined the effect of esomeprazole, omeprazole, or lansoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel.
No. Lansoprazole and AZD4635 solid formulation is a combination product that contains lansoprazole plus AZD4635. Lansoprazole alone is a proton pump inhibitor, while the combination is an investigational solid oral formulation developed by AstraZeneca. The two are related but not interchangeable.